Annual revenue in 2025 reached KRW 191.8 billion, up 9.1% from KRW 175.7 billion in 2024, the largest figure among 2022-2025.
Operating profit plunged from KRW 7.97 billion in 2022 to KRW 6.93 billion in 2023 (down 13.1%) and KRW 181 million in 2024 (down 97.4%), before rebounding to KRW 4.16 billion in 2025, up 2,200.3% year on year.
The operating margin fell to 0.1% in 2024 before recovering to 2.2% in 2025, with the highest margin in the 2022-2025 span recorded in 2022 at 4.9%.
Net profit attributable to controlling shareholders swung from a loss of KRW 165 million in 2022 to a profit of KRW 6.12 billion in 2023, back to a loss of KRW 575 million in 2024, and then to a profit of KRW 2.52 billion in 2025.
Net income including non-controlling interests followed the same pattern: a loss of KRW 165 million in 2022, profit of KRW 6.12 billion in 2023, loss of KRW 575 million in 2024, and profit of KRW 2.52 billion in 2025.
Operating cash flow was positive at KRW 11.6 billion in 2022 but turned negative for three straight years at -KRW 4.55 billion in 2023, -KRW 2.37 billion in 2024 and -KRW 123 million in 2025, though the size of the outflow has gradually narrowed.
On a quarterly basis, revenue slowed from KRW 51.6 billion in the third quarter of 2025 to KRW 48.7 billion in the fourth quarter (down 5.5%) and KRW 46.5 billion in the first quarter of 2026 (down 4.7%), before rising to KRW 55.6 billion in the second quarter (up 19.7%) and KRW 56.3 billion in the third quarter of 2026 (up 1.2% quarter on quarter and 9.1% year on year), marking two consecutive quarters of growth from the first-quarter 2026 trough.
Quarterly operating profit fell from KRW 3.46 billion in the third quarter of 2025 to KRW 42.67 million in the fourth quarter, then rebounded to KRW 2.52 billion in the first quarter of 2026 (up 5,809.1%), eased to KRW 976 million in the second quarter (down 61.3%), and rose to KRW 2.44 billion in the third quarter of 2026 (up 149.9% quarter on quarter, down 29.4% year on year).
Net profit attributable to controlling shareholders bottomed at KRW 268 million in the fourth quarter of 2025 and rose for three straight quarters to KRW 420 million, KRW 1.21 billion and KRW 1.71 billion through the third quarter of 2026, with the trailing four-quarter total (fourth quarter 2025 through third quarter 2026) reaching KRW 3.61 billion.
The profit improvement has been attributed in part to expanded prescriptions of the dementia combination drug Demduo, which reportedly captured more than 60% share of the donepezil-memantine combination market by prescription value in its first year, while a 20.8% year-on-year reduction in first-half recurring R&D expenses was also cited as contributing to the operating-profit gain.